EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The importance of World Health Organization international reference standards in the product life cycle of biosimilars

Hye-Na Kang, Meenu Wadhwa, Ivana Knezevic, Chris Burns, Elwyn Griffiths

Annals of the New York Academy of Sciences · 2024

DOI: 10.1111/nyas.15217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the New York Academy of Sciences, 2024. Verfasst von Hye-Na Kang und 4 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Reference Standards, World Health Organization. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, The Norwegian Agency for Development Cooperation, The Ministry of Health and Welfare of Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Technological advances in analytics, as well as scientific and regulatory knowledge and experience gained from biosimilar development/approvals over the last decade, enabled the World Health Organization (WHO) in 2022 to revise its guidelines on the evaluation of biosimilars. Among the revisions, there is more reliance on analytical and functional aspects to prove similarity (and likely fewer clinical requirements). WHO international reference standards for biosimilars provide additional confidence to regulators looking for evidence‐ and data‐based regulatory convergence in scientific and technical measures of quality attributes. These standards serve as a benchmark for harmonizing the bioactivity or potency of biosimilars, ensuring their future sustainability. This article discusses the availability and role of WHO international reference standards throughout the product life cycle of biosimilars.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsReference StandardsWorld Health OrganizationHumansDrug Approval

Stichwörter der Autor:innen

WHOaccessbiosimilarinternational reference standardsregulation

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland.
  • Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.
  • Independent Consultant, Surrey, UK.

Förderung

  • World Health Organization
  • The Norwegian Agency for Development Cooperation
  • The Ministry of Health and Welfare of Republic of Korea

Zitieren

APA

Kang, H. N., Wadhwa, M., Knezevic, I., Burns, C., & Griffiths, E. (2024). The importance of World Health Organization international reference standards in the product life cycle of biosimilars. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.15217

Vancouver

Kang HN, Wadhwa M, Knezevic I, Burns C, Griffiths E. The importance of World Health Organization international reference standards in the product life cycle of biosimilars. Annals of the New York Academy of Sciences. 2024. doi:10.1111/nyas.15217

BibTeX
@article{Kang2024,
  author = {Kang, Hye-Na and Wadhwa, Meenu and Knezevic, Ivana and Burns, Chris and Griffiths, Elwyn},
  title = {The importance of World Health Organization international reference standards in the product life cycle of biosimilars},
  journal = {Annals of the New York Academy of Sciences},
  year = {2024},
  doi = {10.1111/nyas.15217}
}
Kostenlos starten →